OK, so XCHO has exclusive rights to market Cobroxin in the U.S. Is this true?
Why did NPHC sell those rights to XCHO? XCHO doesn't appear to have any particular advantages - total sales last quarter was $13,500. Total assets are $1,050,000.
Here is how XCHO describes itself - "XenaCare Holdings, Inc. (the “Company”, “XenaCare”, “XC Holdings”, “we”, “us” or “our”) was organized under the laws of Florida in June 2005 to formulate, market and distribute a line of clinical, life style performance and protective nutrition supplement products (“NSPs”)."
XCHO is a 12 cent stock with 50 million shares outstanding.
NPHC is a 45 cent stock with 220 million outstanding -
plus these new shares I guess: "On August 20, 2009, our Board of Directors authorized the offer and sale of our common stock at $0.08 per share. From September 1, 2009 through September 22, 2009, we sold 34,948,750 million common shares (the “Shares”) to 65 accredited investors for aggregate proceeds of $2,795,900."
doesn't make sense